Form 4: Centessa Pharmaceuticals Director Arjun Goyal Granted 40,000 Stock Options

Centessa Pharmaceuticals plc director Arjun Goyal was granted 40,000 stock options with an exercise price of $12.43 per share, aligning his interests with shareholder value.

Summary

• Arjun Goyal, a Director of Centessa Pharmaceuticals plc (CNTA), was granted 40,000 share options.
• The transaction date for this grant was June 20, 2025.
• Each option has an exercise price of $12.43.
• The options are exercisable from June 20, 2025, and expire on June 20, 2035.
• The 40,000 options represent the right to buy 40,000 Ordinary Shares of Centessa Pharmaceuticals plc.
• The shares subject to these options will vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's next annual meeting of shareholders, contingent on continued service as a director through the applicable vesting date.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is generally a positive signal, indicating alignment of interests and a belief in future stock appreciation, though it's a routine compensation event rather than a major strategic announcement.

Positives

• The grant of 40,000 stock options to Director Arjun Goyal aligns management's interests with those of shareholders, as the options gain value only if the stock price increases above the exercise price of $12.43.
• The long expiration date of June 20, 2035, provides a significant window for the options to become in-the-money, indicating a long-term incentive for the director.

Negatives

• No specific negative information is contained within this Form 4 filing.

Risks

• The value of the granted stock options is subject to the future performance of Centessa Pharmaceuticals plc's stock price; if the stock price does not exceed the exercise price of $12.43, the options may expire worthless.
• Vesting of the options is contingent on Arjun Goyal's continued service as a director, meaning the options could be forfeited if service ceases before vesting conditions are met.

Future Outlook

This Form 4 filing does not provide a general future outlook for the company, but the grant of long-term stock options suggests an expectation of future value creation by the company's board.

Management Comments

• No direct management comments or quotes are included in this Form 4 filing.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industry, including companies like Centessa Pharmaceuticals, serving as a key component of executive and director compensation packages designed to align leadership incentives with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to directors is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology. While specific grant sizes vary based on company size, director responsibilities, and compensation philosophy, a grant of 40,000 options for a director is within typical ranges for a company of Centessa's profile.
• Similar grants are observed at comparable biotech firms such as BridgeBio Pharma (BBIO) or Recursion Pharmaceuticals (RXRX) for their non-executive directors, often tied to performance or time-based vesting schedules.
• The exercise price being at or near the market price on the grant date is also standard for incentive stock options.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align the director's financial interests with those of shareholders, potentially incentivizing decisions that enhance long-term shareholder value.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The granted share options will vest in full on the earlier of the first anniversary of the grant date (June 20, 2026) or the Issuer's next annual meeting of shareholders, subject to continued service.
• Upon vesting, Arjun Goyal will have the right to exercise these options to purchase Ordinary Shares of Centessa Pharmaceuticals plc at $12.43 per share until the expiration date of June 20, 2035.

Key Dates

Keywords

Centessa Pharmaceuticals, CNTA, Form 4, stock option grant, director compensation, insider transaction, equity incentive, Arjun Goyal, beneficial ownership